MedTrace Logo

A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer

NCT02387996 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 270

Last updated 2022-11-01

Study results available
· View outcomes & findings →

Summary

The purpose the study is to measure the effect of nivolumab (BMS-936558) in reducing tumor size in subjects with metastatic or unresectable bladder cancer.

Conditions

  • Various Advanced Cancer

Interventions

DRUG

Nivolumab

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-09
Primary Completion
2016-04-15
Completion
2021-11-12

Countries

  • United States
  • Australia
  • Belgium
  • Czechia
  • Finland
  • Germany
  • Italy
  • Japan
  • Poland
  • Spain
  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02387996 on ClinicalTrials.gov